Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial
Year: 2025
Type: article
Language: en
Topic: PI3K/AKT/mTOR signaling in cancer
Authors and affiliations:
raw_author_name: P. Schmid
raw_affiliation_strings: Centre of Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: p.schmid@qmul.ac.uk
raw_author_name: H.L. McArthur
raw_affiliation_strings: Department of Internal Medicine, UT Southwestern Medical Center, Dallas, USA
raw_author_name: J. Cortés
raw_affiliation_strings: Breast Cancer Unit, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain; Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Ridgewood, USA
raw_author_name: B. Xu
raw_affiliation_strings: Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
raw_author_name: F. Cardoso
raw_affiliation_strings: Breast Unit, Champalimaud Clinical Center and Advanced Breast Cancer (ABC) Global Alliance, Lisbon, Portugal
raw_author_name: M. Casalnuovo
raw_affiliation_strings: CENIT Centro Medico de Neurociencias, Buenos Aires, Argentina
raw_author_name: U. Demirci
raw_affiliation_strings: Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkey
raw_author_name: R. Freitas-Junior
raw_affiliation_strings: Hospital Araujo Jorge, Goiânia, Brazil
raw_author_name: J. Ghosh
raw_affiliation_strings: TATA Medical Center, West Bengal, India
raw_author_name: R. Hegg
raw_affiliation_strings: São Paulo State Government Women's Health Reference Center, São Paulo, Brazil
raw_author_name: H. Iwata
raw_affiliation_strings: Department of Breast Oncology, Nagoya City University, Nagoya, Japan
raw_author_name: I. Karnaukhov
raw_affiliation_strings: Department for Coordination of Experimental and Clinical Research, Saint Petersburg State University Hospital, Saint Petersburg, Russia
raw_author_name: Y.L. Chuken
raw_affiliation_strings: Department of Internal Medicine, iCan Oncology Center, Monterrey, Mexico
raw_author_name: M. Nechaeva
raw_affiliation_strings: Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russia
raw_author_name: M.E. Robson
raw_affiliation_strings: Inherited Breast Cancer Genomics, Niehaus Center, Memorial Sloan Kettering Cancer Center, New York, USA
raw_author_name: R. Villalobos-Valencia
raw_affiliation_strings: Consultorio Centro de la Torre Medica Dalinde (Oncologia Medica), Mexico City, Mexico
raw_author_name: T. Yamashita
raw_affiliation_strings: Department of Breast Surgery, Kanagawa Cancer Center, Yokohama, Japan
raw_author_name: B. Zurawski
raw_affiliation_strings: Centrum Onkologii im. Łukaszczyka, Romanowska, Poland
raw_author_name: E.C. de Bruin
raw_affiliation_strings: Oncology R&D, AstraZeneca, Cambridge, UK
raw_author_name: L. Grinsted
raw_affiliation_strings: Oncology R&D, AstraZeneca, Cambridge, UK
raw_author_name: C. D’Cruz
raw_author_name: A. Foxley
raw_affiliation_strings: Oncology R&D, AstraZeneca, Cambridge, UK
raw_author_name: Y.H. Park
raw_affiliation_strings: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea